EHL BIO overview
Stem-cell approach for Autoimmune Disease
The EHL source focuses on immune balance and the interaction between stem cells and immune signalling. Because autoimmune conditions vary widely, assessment is condition- and patient-specific.
Cell technology and manufacturing
EHL BIO publishes information on cell isolation, culture, banking and quality control through its GMP centre.
View EHL technologyAssessment at EHL Cell Clinic
A clinician must assess the condition, overall health, treatment history and fit with an applicable Korean plan for each patient.
Meet the hospital and care teamKorean regenerative-medicine law
Korea provides a regulated advanced regenerative-medicine treatment pathway
Korea's amended law, effective 21 February 2025, allows designated advanced regenerative-medicine institutions to submit treatment plans for committee review and charge for treatment delivered under a plan found suitable.
The law does not automatically authorise every stem-cell type for every disease. Access depends on the institution's status, cell type, condition, a suitable reviewed plan and individual patient assessment.
Frequently asked questions
Original EHL BIO disease source
http://ehlbio.co.kr/eng/cure/autoimmuneInformation sources
- Korean National Law Information Center — Advanced Regenerative Bio Act · retrieved 11 Oct 2026
- K-ARM — Advanced regenerative-medicine treatment plan review · retrieved 11 Oct 2026
- Korean Ministry of Health and Welfare — designated institutions and treatment plans · retrieved 11 Oct 2026